Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 4,139 Shares of Stock

by · The Cerbat Gem

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William Peters sold 4,139 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $25.00, for a total transaction of $103,475.00. Following the transaction, the chief financial officer directly owned 168,707 shares in the company, valued at $4,217,675. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Stock Up 2.6%

Shares of AMPH traded up $0.64 during mid-day trading on Wednesday, hitting $24.96. The company’s stock had a trading volume of 504,550 shares, compared to its average volume of 520,503. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of 14.77, a PEG ratio of 4.72 and a beta of 0.92. Amphastar Pharmaceuticals, Inc. has a 52-week low of $16.65 and a 52-week high of $29.52. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The company’s 50-day moving average is $21.50 and its 200-day moving average is $20.41.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million during the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC increased its holdings in shares of Amphastar Pharmaceuticals by 5.3% during the fourth quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock valued at $243,000 after acquiring an additional 457 shares in the last quarter. Bessemer Group Inc. boosted its stake in Amphastar Pharmaceuticals by 1.0% in the 1st quarter. Bessemer Group Inc. now owns 122,046 shares of the company’s stock worth $2,391,000 after purchasing an additional 1,156 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Amphastar Pharmaceuticals by 43.6% in the 4th quarter. Hantz Financial Services Inc. now owns 4,484 shares of the company’s stock worth $120,000 after purchasing an additional 1,362 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth approximately $39,000. Finally, Vestcor Inc grew its position in Amphastar Pharmaceuticals by 74.6% during the 4th quarter. Vestcor Inc now owns 16,383 shares of the company’s stock worth $439,000 after purchasing an additional 7,000 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of a number of analyst reports. Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Bank of America reiterated an “underperform” rating and issued a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Wells Fargo & Company increased their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Reduce” and an average price target of $22.50.

Check Out Our Latest Analysis on AMPH

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.

Featured Articles